For most people, creatine is associated with strength, muscle growth and exercise recovery. But creatine’s underlying role is broader: it helps cells rapidly regenerate energy during periods of high demand. That makes creatine relevant not only to muscle cells, but also to energy-intensive cells in the brain and immune system. New UCLA research has now examined how creatine availability affects dendritic cells, specialized immune cells that help direct T-cell responses.
Researchers from UCLA investigated why dendritic cells inside tumors have different metabolic demands than dendritic cells in healthy tissue. They found that tumor-infiltrating dendritic cells increased expression of SLC6A8, the transporter that moves creatine into cells. The team then studied what happened when dendritic cells could not access creatine and when creatine availability was increased in a mouse melanoma model.
Dendritic cells are specialized antigen-presenting cells that help connect the body’s innate and adaptive immune responses. They patrol tissues, capture fragments of pathogens or abnormal cells, and carry them to lymph nodes, where they present them to T cells. This process, called antigen presentation, is what tells the immune system exactly what to attack.
A few functions make dendritic cells especially important:
Because dendritic cells help activate and guide T-cell responses, researchers are increasingly interested in how dendritic-cell metabolism affects immune activity inside tumors.
Creatine helps buffer cellular energy. Cells use ATP, or adenosine triphosphate, as an immediate energy source. During periods of high demand, phosphocreatine can donate a phosphate group to help regenerate ATP. This allows cells to maintain energy availability for short periods when demand rises rapidly.
This is well understood in muscle tissue, where creatine supplementation increases phosphocreatine stores and supports short bursts of intense effort. The creatine-phosphocreatine system is also present in the brain, where researchers are studying its potential relevance to brain energetics and certain measures of cognitive performance. Results vary by population, dietary intake and the outcome being measured.
Cells primarily rely on a transporter known as SLC6A8, often called the creatine transporter, to move creatine across the cell membrane. The UCLA researchers found that SLC6A8 expression was higher in tumor-infiltrating dendritic cells than in comparable dendritic cells from healthy tissue.
To understand why, the team studied dendritic cells engineered to lack the creatine transporter entirely. These cells showed impaired survival, reduced activation, and a weaker ability to prime CD8+ T cells against tumors. In other words, when dendritic cells couldn’t pull in creatine, their ability to do their job suffered. The researchers then examined whether increasing creatine availability could alter dendritic-cell activation and antitumor immune activity in their experimental models.
Important context: The antitumor experiment involved creatine administered to mice with melanoma tumors. It did not test oral creatine capsules or powder in people, and it did not evaluate Project Creatine or any branded creatine product.
Dr. Lili Yang’s laboratory had previously studied how creatine availability affects CD8+ T-cell metabolism and antitumor activity. The new research examined whether creatine also influences dendritic cells, which help activate and guide those T-cell responses.
Researchers used several experimental approaches:
| Study observation | Scientific interpretation |
|---|---|
| SLC6A8 was elevated in tumor-infiltrating dendritic cells | Creatine transport may be important to the metabolic demands of these cells. |
| Removing SLC6A8 weakened dendritic-cell function | Normal creatine transport contributed to survival, activation and T-cell priming. |
| Creatine treatment slowed tumor growth in mice | Supports further preclinical investigation; it does not establish a human cancer benefit. |
| Creatine increased cDC1 abundance and activation markers | Suggests enhanced dendritic-cell activity in the mouse tumor environment. |
| Intracellular ATP increased | Provides a possible energy-related mechanism for the observed effects. |
Cancer immunotherapies have produced meaningful and sometimes durable responses for certain patients, but results vary widely by cancer type, treatment and patient characteristics. Many existing therapies focus on activating or removing inhibitory signals from T cells. Researchers are also exploring approaches that act earlier in the immune response, including strategies involving dendritic cells.
The researchers proposed two areas for future study. One is whether creatine could support immune-cell activity when used alongside existing cancer treatments. The other is whether creatine could improve the preparation of dendritic-cell-based therapies in the laboratory before those cells are administered to patients. Both possibilities remain experimental and require clinical testing.
These findings should not be interpreted as a recommendation for people with cancer to begin creatine supplementation. The tumor results came from a mouse melanoma model, and the human experiments involved cells studied outside the body. The research did not establish an effective oral dose, demonstrate improved treatment outcomes in patients or evaluate interactions with cancer medications.
This study provides mechanistic and preclinical evidence, not clinical treatment guidance.
The study contributes to a broader area of research examining how the creatine-phosphocreatine system supports energy-intensive tissues and cells.
The strongest established uses of creatine remain related to exercise performance, strength and training adaptation. The UCLA findings expand the scientific discussion around cellular energy metabolism, but they should not yet be translated into consumer claims about immune enhancement or cancer outcomes.
Creatine monohydrate has limited solubility in water, and some people experience gastrointestinal discomfort when taking larger amounts at once. However, it is generally well absorbed and has the largest body of evidence supporting its safety and effectiveness.
Project Creatine uses a self-emulsifying, lipid-based delivery system designed to improve dispersion and increase measured creatine exposure from a smaller administered amount. This delivery technology was not evaluated in the UCLA dendritic-cell study, and the UCLA findings should not be used as evidence that Project Creatine improves immune function or cancer outcomes.
When choosing a creatine product, consider the quality of the ingredients, third-party testing, serving format, dosing instructions and whether the product’s claims are supported by product-specific evidence.
The UCLA study did not evaluate Project Creatine, CreaXorb, BioSNEDS or any other branded creatine supplement. It also did not compare oral creatine products or determine whether one delivery system has a greater effect on dendritic cells.
The study is relevant to Project Creatine’s broader interest in creatine availability and cellular energy. However, Project Creatine’s absorption and product-performance claims must be supported by separate, product-specific research and should not be inferred from this UCLA study.
For conventional creatine monohydrate, a commonly studied maintenance intake is 3 to 5 grams per day. Some protocols use a temporary loading phase, although loading is not required. Daily consistency is generally more important than precise workout timing.
Product formulations can differ, so consumers should follow the serving instructions for the specific product they are using. Anyone receiving treatment for cancer or managing a medical condition should discuss supplement use with their qualified healthcare professional.
The UCLA dendritic cell study adds to emerging research on creatine’s role in cellular energy metabolism. In mouse tumors and cultured human cells, creatine availability supported dendritic-cell energy, activation and signaling. In the mouse melanoma model, creatine treatment was also associated with slower tumor growth.
These findings are promising but preliminary. Researchers did not test oral creatine in cancer patients, and the study does not show that creatine supplements prevent, treat or cure cancer. It also does not establish that Project Creatine or another branded product improves dendritic-cell activity.
For now, the research offers a deeper look at how creatine may support the energy demands of specialized cells. Clinical studies will be needed before those findings can be translated into recommendations for cancer care or immune health.
Dendritic cells are specialized antigen-presenting immune cells. They capture and process abnormal material and help activate T cells against specific targets.
The researchers found that creatine transport supported dendritic-cell survival, energy metabolism and activation in experimental models. Creatine treatment also slowed melanoma tumor growth in mice.
No. The tumor findings came from a mouse model and did not test ordinary oral creatine supplementation in people.
No. The research was preclinical and does not show that creatine prevents, treats or cures cancer in humans.
No. The study did not evaluate Project Creatine, CreaXorb, BioSNEDS or any branded consumer creatine product.
SLC6A8 is the primary transporter that helps move creatine from outside a cell into the cell.
Dendritic cells need energy to survive, process antigens, migrate, become activated and communicate with T cells and other immune cells.
Yes. The strongest established evidence for creatine supplementation continues to involve strength, high-intensity exercise, training performance and lean-mass development.
This article is for educational purposes only and is not medical advice. The research discussed included mouse experiments and laboratory studies involving human cells. It does not demonstrate that creatine supplements prevent, treat or cure cancer in humans. Project Creatine, CreaXorb and BioSNEDS were not evaluated in the UCLA study. People receiving cancer treatment or managing a medical condition should consult their qualified healthcare professional before using dietary supplements.
Evidence-based creatine guidance
